Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Acquisition and Trading Update

20 Dec 2021 07:00

RNS Number : 1142W
Sopheon PLC
20 December 2021
 

SOPHEON PLC

("Sopheon," the "Company" or the "Group")

 

Acquisition and Trading Update

Initiation of M&A strategy coupled with solid execution of revenue objectives for the year

Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, is pleased to announce the acquisition of the business and assets of ROI Blueprints LLC ("ROIB"), a cloud-based solution focused on detailed enterprise planning and execution. The Group is also providing a trading update for the current year ending 31 December 2021.

 

ROI Blueprints

 

ROIB is a cloud-based project and portfolio SaaS solution designed to help organizations drive operational execution management of corporate initiatives. Integrating the ROIB solution with Sopheon's Accolade product will extend the value of Sopheon's offering and expand market reach. It will also further accelerate Sopheon's migration towards cloud and SaaS. In addition to the cross-selling opportunities, these attributes will further underpin the Group's solid retention metrics. ROIB was founded in 2014 by industry domain experts Ketan Jahagirdar and Russ Fuja following years of expertise working with enterprise leaders such as Motorola, Accenture, and Diamond Management Consultants.

 

Greg Coticchia, CEO of Sopheon commented: "We are excited to add ROIB to the Sopheon family, further enhancing our ability to link and connect corporate innovation planning and operational execution for improved risk mitigation and decision making. ROIB not only brings new capability to our offering but also represents a wealth of knowledge which will contribute to our future roadmap. We see this as a technology acquisition that will improve our time to market for a key product capability. I believe it would have taken us at least two years of material investment to develop equivalent capability in house."

 

The transaction is structured as an asset purchase. Initial consideration of US$1.5m is payable in cash, funded from the Group's existing resources of over $24m at 30 November 2021. An additional, contingent deferred earn-out of up to $1.5m is payable over the next three years, linked to product deliverable and revenue targets. Up to one-third of the earn-out is payable in Sopheon shares valued at £9.35 per share, the mid-market closing price on 16 December 2021. The business is expected to record pro-forma revenues of approximately $0.1m in 2021. Sopheon will also take on an annual cost base of approximately $0.5m and net financial assets of approximately nil, before valuation of intangibles and goodwill. As noted above, Sopheon revenues are expected to respond positively to the added market reach afforded by the ROIB capability, which adds upsell opportunity and the potential for a higher acquisition of new customers.

 

Ketan Jahagirdar, ROIB co-founder and CEO commented: "Sopheon represents a unique market fit for us. We have built what we believe is the most compelling platform for project and portfolio execution. We are very excited that we can now accelerate further development and commercialization as part of the overall Sopheon product offering, leveraging Sopheon's proven sales and marketing resources."

 

Trading update

 

In our half-year report issued on 25 August 2021, we reported rising commercial traction across our core performance metrics as we migrated the business to a more recurring model. We are pleased to report that we expect revenues and EBITDA for the year ended 31 December 2021 to be comfortably in line with market expectations, coupled with solid progress on building annual recurring revenue. The closing weeks of the year remain busy with commercial activity. The Board will update shareholders further on the full year outturn at the end of January.

 

Andy Michuda, chairman of Sopheon, commented: "I am delighted to be embarking on the M&A strategy that we have previously signposted, with the acquisition of ROI Blueprints. It adds depth to our product offering, and brings important intellectual property and capability to support our cloud transition. Coupled with our strong organic execution, this is a great way to finish the year".

For further information contact:

 

Andy Michuda (Executive Chairman)

Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Edward Whiley (Corporate Finance)

Alice Lane/Sunila da Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (596/2014/EU) as it forms part of UK domestic law by virtue of the European Union (withdrawal) act 2018 ("MAR").

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions, including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management, and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUKRNRAAUUAAA
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.